Fast Facts: EGFR Exon 20 Insertion Mutations in NSCLC
Lung cancer is still a major cause of death globally, but the development of personalized, precision medicine has had a marked effect on treatment management and improved clinical outcomes, particularly for those with advanced stage non-small-cell lung cancer (NSCLC). EGFR mutations are the third mo...
Αποθηκεύτηκε σε:
| Κύριοι συγγραφείς: | , , , |
|---|---|
| Μορφή: | Livre numérique |
| Γλώσσα: | Anglais |
| Έκδοση: |
Basel :
S. Karger
2022.
Basel : |
| Διαθέσιμο Online: | https://www.karger.com/Book/Home/282630 Accès Université d'Orléans et IFPM |
| Σημείωση: |
Karger Fast Facts |
| Autres localisations: | Voir dans le Sudoc |
| Edition sous un autre format: | • Fast Facts: EGFR Exon 20 Insertion Mutations in NSCLC, 9783318070200 |
| LEADER | 02153nam a22002537a 4500 | ||
|---|---|---|---|
| 001 | 1326201 | ||
| 008 | 230215s2022 xx ||| |||| 00| 0 eng d | ||
| 009 | PPN26770867X | ||
| 020 | |a 9783318071368 | ||
| 041 | 0 | |a eng | |
| 100 | 1 | |a Rotow, Julia. | |
| 245 | 1 | 0 | |a Fast Facts: EGFR Exon 20 Insertion Mutations in NSCLC |c Julia Rotow ; Parneet Cheema, Pasquale Pisapia, Giancarlo Troncone. |
| 260 | |a Basel : |b S. Karger. | ||
| 260 | |a Basel : |b S. Karger, |c 2022. | ||
| 500 | |a Karger Fast Facts | ||
| 506 | |a Accès libre pour tout établissement ou utilisateur ayant un compte sur la plateforme de l'éditeur | ||
| 520 | |a Lung cancer is still a major cause of death globally, but the development of personalized, precision medicine has had a marked effect on treatment management and improved clinical outcomes, particularly for those with advanced stage non-small-cell lung cancer (NSCLC). EGFR mutations are the third most common mutation found in patients with advanced stage NSCLC. First-line treatment with a traditional epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is indicated for most patients, but not for patients with EGFR exon 20 insertion mutations (ex20ins). Instead, recent approvals of an EGFR ex20ins-specific TKI (mobocertinib) and a bispecific antibody (amivantamab) targeting both EGFR and mesenchymalepithelial transition factor (MET) offer the potential for improved outcomes in this patient population. Furthermore, new approaches to treatment continue to be developed and trials for new agents with greater activity against ex20ins mutations are ongoing | ||
| 700 | 1 | |a Cheema, Parneet. |4 aut | |
| 700 | 1 | |a Pisapia, Pasquale. |4 aut | |
| 700 | 1 | |a Troncone, Giancarlo. |4 aut | |
| 776 | 0 | |t Fast Facts: EGFR Exon 20 Insertion Mutations in NSCLC |z 9783318070200 | |
| 856 | 4 | |u https://www.karger.com/Book/Home/282630 | |
| 856 | 4 | |5 452349901:858580950 |u https://ezproxy.univ-orleans.fr/login?url=https://www.karger.com/Book/Home/282630 |z Accès Université d'Orléans et IFPM | |
| 997 | |0 1326201 |1 Livre numérique |a Ressource numérique |b INSA |b ENSA |c 0/Bibliothèque numérique/ |c 1/Bibliothèque numérique/Autre ressource numérique/ | ||